Y-mAbs claims FDA OK for neuroblastoma drug Danyelza
Body makes special case due to rarity of the disease
Taking lenient stance, NICE backs neuroblastoma drug
EUSA Pharma looks to further in-licensing to build growth
Company can move in after United Therapeutics withdrew its product Unituxin
EUSA Pharma approval fills gap in neuroblastoma market
Unituxin too costly for use in children, NICE says.
Brain cancer drug too expensive, says NICE